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Abstract
Background: Early detection of melanoma is of great importance to reduce mortality. Discovering new melanoma
biomarkers would improve early detection and diagnosis. Here, we present a novel approach to detect volatile compounds
from skin.
Methods and Findings: We used Head Space Solid Phase Micro-Extraction (HS-SPME) and gas chromatography/mass
spectrometry (GC/MS) to identify volatile signatures from melanoma, naevi and skin samples. We hypothesized that the
metabolic state of tissue alters the profile of volatile compounds. Volatiles released from fresh biopsy tissue of melanoma
and benign naevus were compared based on their difference in frequency distribution and their expression level. We also
analyzed volatile profiles from frozen tissue, including skin and melanoma.
Conclusions: Three volatiles, 4-methyl decane, dodecane and undecane were preferentially expressed in both fresh and
frozen melanoma, indicating that they are candidate biomarkers. Twelve candidate biomarkers evaluated by fuzzy logic
analysis of frozen samples distinguished melanoma from skin with 89% sensitivity and 90% specificity. Our results
demonstrate proof-of-principle that there is differential expression of volatiles in melanoma. Our volatile metabolomic
approach will lead to a better understanding of melanoma and can enable development of new diagnostic and treatment
strategies based on altered metabolism.
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Introduction
Although the idea that changes in tissue are an indication of
disease dates back to the ancient Greeks [1], full understanding of
many pathological processes at the molecular system level is still
lacking. In the current post-genomic era, we are faced with an
enormous amount of data from genomic, transcriptomic, and
proteomic studies. Systems biology approaches are being used to
integrate these large data sets in an attempt to understand how
macromolecular networks may control phenotype. Metabolomics,
the study of small molecule metabolites is now emerging. The
metabolome is defined as the complete set of metabolites, low
molecular weight intermediates which are context dependent,
varying according to the physiological, developmental or patho-
logical state of the cell, tissue, organ or organism [2]. The
advantage of metabolomics is that metabolites are downstream of
both transcription and translation, at the endpoint of the ‘‘omics’’
cascade and thus may be most predictive of phenotype [3,4].
Because of the chemical diversity of metabolites, no single platform
for their detection can be used. Currently used platforms include
NMR spectroscopy, LC/MS, GC/MS and MS The study of the
metabolome can be divided into two classes: 1. metabolic profiling,
which relates to the study of a group of metabolites specific for a
particular metabolic pathway; and 2. metabolic fingerprinting,
which compares patterns (i.e. fingerprints) of metabolites that
change in response to disease [5].
In this paper, we studied skin, naevi and melanoma volatile
metabolomes; their volatile metabolomic fingerprints or signa-
tures. Our hypothesis is that melanoma tissue emits unique volatile
compounds which are either direct metabolic products of
melanoma patho-physiology or epiphenomena. In order to study
volatile metabolic compounds, we used gas chromatography/mass
spectrometry (GC/MS), a powerful method for studying volatile
organic compounds. First, we collected volatiles by using the rapid
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method (HS-SPME) initially developed by J. Pawliszyn [6].
Volatiles from the collection fiber were easily desorbed into a
gas chromatograph, separated on a non-polar column, and
detected by a mass spectrometer. The identity of each compound
was determined by comparison with a mass-spectral database.
Analysis of volatile components from fresh melanoma and naevi,
as well as from frozen skin and melanoma samples, indicate that a
differential volatile profile of melanoma does indeed exist.
Results
The volatile collection preserves the tissue morphology
The diagnosis of melanoma is based on histological analysis of
tissue biopsies and remains the primary modality of detection.
Here, we show that our method of volatile collection does not alter
tissue morphology. Five naevi samples and three melanoma lesions
big enough to obtain two parallel 3-mm samples were used for both
histology (H&E staining) and volatile collection analysis. The first
biopsy sample from each naevus and melanoma was put straight
into formalin, embedded in paraffin, sectioned and stained using
standard histopathological methods (Figure 1A and C). The
second, parallel biopsy sample from each naevus and melanoma
was first subjected to the volatile collection by using our HS-SPME
method (Figure 1E) and volatile analysis. Less than three hours
after biopsy collection and volatile analysis, samples were put into
formalin and processed for histology (Figure 1B and D). Because
the histological samples from the two groups were indistinguish-
able, we conclude that our volatile analysis of tissue biopsies does
not alter tissue morphology. Thus, our volatile collection does not
change tissue appearance and does not interfere with standard
clinical procedures related to melanoma diagnosis.
Comparative analysis of volatile compounds in the fresh
naevi and melanoma
Demographic data for volunteers and melanoma patients used
to obtain fresh tissue, as well as data obtained from the
Cooperative Human Tissue Network bank (CHTN) regarding
frozen tissue are summarized in the Table S1. In addition,
histopathology reports for the 5 fresh melanoma biopsy samples
are presented in Table S2. Analysis of the volatile molecules
collected from fresh naevi (n=25) and fresh melanoma samples
(n=5) revealed complex volatile chromatographic signatures
(Figure 2, C and F). Some peaks in the chromatograms were only
present in melanoma group (indicated with ***), while some were
increased (**) or decreased (*) in the melanoma group as compared
to the naevi group. In total, using AMDIS (Automated Mass
Spectral Deconvolution and Identification software) and the NIST
2.0 mass spectral library, we detected and identified 325 unique
volatile compounds from naevi (N) and melanoma (M) samples
with $60% confidence.
Thirty two compounds were present in 60% of the samples from
the naevi group. Most of these compounds were also detected in
both melanoma and air samples (blanks). Only pyridine and 3-
hexanol appeared to be specific for naevi (Figure 2, G and J).
Pyridine is present at 60% frequency in naevi group. It was
detected only in one melanoma sample and it was not detected in
air samples. 3-hexanol was detected exclusively in the naevi group.
We also identified dimethyl benzenamine (at carbons 2,3;2,4;2,5
or 2,6) as a common volatile compound present in both naevi and
melanoma (Figure 2, M, N and O). Compounds that differ only in
a methyl group position (as is the case with the dimethyl
benzenamine) have similar mass spectra and thus are hard to
distinguish using gas chromatography/mass spectroscopy.
Statistical analysis of melanoma differential volatiles
identified from fresh biopsy samples
Differential components were statistically identified based on
two criteria, the amplitude or the frequency. A difference in
amplitude was defined as a statistical significance of the difference
in the pair-wise mean value (‘‘Total Integrated Signal’’ or ‘‘area
under the peak’’) (Student t-test) of expression between groups
(naevi ‘‘N’’, melanoma ‘‘M’’, and blank ‘‘B’’, ambient air sample).
A difference in frequency was defined as the statistical significance
of the difference in the frequency of appearance (Cochran-Mantel
Haenszel test). We looked for the relative frequencies of the
volatiles in each group and tested their significant difference in
distribution by using the odds/ratio (comparing a frequency in M
vs frequency in N group) and Cochran-Mantel Haenszel test (to
determine the likelihood of seeing a compound in the M vs N
group); an odds ratio of .2.5 and a metabolite present in 40% or
more melanoma biopsies indicated a potential biomarker or
molecule of interest.
We found 21 volatile compounds present at a significantly
different frequency between the two groups (Table 1); among them
alkanes (e.g., nonane), methylated alkanes, alkenes (e.g., tridecene)
were abundant. Phthalate, butanal, dimethylsulfone and indole,
were all 16X more likely to be detected in the melanoma then in
the naevi group. We identified the presence of longer chain
alcohols, from dodecanol to hexadecanols (C12-C16). Methylated
benzenes (compounds 5-10 in Table 1) were also abundant in the
melanoma group. Although we listed them in the Table 1, the
exact identity, (i.e. the position of the methyl groups) of these
compounds is elusive, since their retention times (between 12–13
minutes) and their mass spectra are very similar.
The summary of the t-tests, where significant differences in the
mean values of the compounds were compared, the associated p-
values together with their structures are presented in Figure 3A, B
and C. It is interesting to note that only acetamide (Figure 3A) and
isopropyl alcohol (Figure 3B) showed decreased levels in the
melanoma group relative to the naevi group; all other compounds
were found to be significantly increased. Xylene was detected in
melanoma but not in naevi. o- and p- xylene have very similar mass
spectra and it is difficult to distinguish them by mass spectrometry.
Xylene is part of the benzene, toluene, ethylbenzene, o-, m- and p-
xylene complex (BTEX), an index of environmental contamination
ofsoil andground waterbypetroleumproducts.Pleasenote that the
procedure for collecting volatiles occurs before any histological
procedure. Thus, the presence of xylene in melanoma and skin
groups (and its absence in naevi) is probably due to intrinsic
physiological processes. Indeed, the regular protocol for embedding
the tissue in paraffin requires xylene. It is used for clearing the tissue
following dehydration step. However, because all of our samples
have been analyzed for volatile compounds before this step and also
because all samples were treated the same way, the presence of
xylene in the melanoma and skin groups is not due to technical or
methodological artifacts.
In summary, the increased presence of methylated alkanes and
benzenes may indicate an increased methylation process in
melanoma. The presence of secondary metabolites of membrane
lipid peroxidation, e.g alkanes (nonane, decane, undecane,
dodecane, tridecane), alkenes (decene, tridecene), aldehydes
(propanal, butanal) may be an indicator of oxidative stress [7,8].
Statistical analysis of differential volatiles from frozen
melanoma and skin samples
The availability of the fresh melanoma tissue is often a limiting
step in the experimental work. Thus, other sources, such as frozen
Melanoma Volatile Biomarkers
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13813Figure 1. Volatile collection preserves the tissue morphology. H&E staining of naevus (A and B) and melanoma (C and D). Histological
analysis of the first punch biopsy sample placed immediately in formalin (A and C). Histological analysis of the second punch biopsy, after collection
of volatiles (B and D). No obvious deterioration of the tissue samples was detected by the histopathologist. E. Volatile collection by HS-SPME
method. Skin, naevi or melanoma 3-mm punch biopsy sample was placed in a small capped vial. PDMS-DVB fiber (red) was exposed to the head-
space above the biopsy sample for 1 hour. After volatile collection, the fiber is retracted, and injected into GC/MS.
doi:10.1371/journal.pone.0013813.g001
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frozen melanoma and 20 frozen skin samples obtained from the
CHTN tissue bank were collected and analyzed. Similar to our
work with fresh samples, analysis of frozen melanoma and frozen
skin revealed differential volatile profiles in the two biopsy sets.
Demographic data and histopathology reports for frozen melano-
ma tissue samples were summarized in the Table S3. In total, 220
compounds in the two sample sets were detected; this is less than
the 325 detected in fresh samples. Out of 18 melanoma samples,
only 3 were skin biopsy samples, the remaining samples were
metastatic melanoma tissue from: lymph node (10), intestine (2),
liver (1), lung (1) and breast (1). Compounds listed in Table 2 were
present at a significantly increased frequency distribution in the
melanoma group vs the skin group. Compounds listed in Table S4
are volatiles detected at a significantly higher distribution
frequency in skin samples. Xylene was detected in the frozen skin
samples. We also detected this compound in fresh melanoma, but
not in the fresh naevi group (see Discussion). Volatiles with
significantly increased mean value and their associated p-values in
melanoma vs skin group are presented in Table 3. Two
compounds, dodecane and 5-methyl dodecane, were significantly
increased in melanoma using either the expression level (Table 3)
or the frequency of distribution (Table 2).
Fuzzy logic-based statistical analysis of the frozen tissue
bank samples
Retention times from the chromatograms obtained from frozen
skin and melanoma samples were used to create a table of test
samples from which volatile compounds relevant for the
discrimination between the skin and melanoma groups were
derived. From a total of 38 samples (18 melanoma and 20 skin
samples), twelve volatile compounds were identified as relevant
and a fuzzy logic prediction algorithm was created. The list of
these compounds with their relevant Goodman Kruskal Lambda
value is presented in Figure 4A. A higher Goodman Kruskal
Lambda value indicates a higher likelihood that a volatile
compound is predictive for melanoma. These potential candidate
markers were evaluated by fuzzy logic analysis and demonstrated
the ability to distinguish melanoma from skin with 89% sensitivity
(16/18) and 90% specificity (18/20). Nonanal is a common and
Table 1. Volatile compounds with significant differences in frequency distribution in fresh melanoma vs fresh naevi samples
(Cochran-Mantel Haenszel test, M-melanoma, N-naevi).
No CAS COMPOUND GROUP M N p-value odds ratio
1 111-84-2 Nonane aliphatic saturated hydrocarbon 5/5 11/25 0.02 14
2 2847-72-5 Decane, 4-methyl aliphatic saturated hydrocarbon 3/5 2/25 0.0051 17
3 25377-82-6 1-Tridecene aliphatic unsaturated hydrocarbon 4/5 7/25 0.03 10
4 5113-87-1 Cyclohexene, 3-methyl-6-(1-methylethenyl)-,
(3R-trans)- (E-isolimonene)
unsaturated monocyclic hydrocarbon 4/5 8/25 0.049 9
5 98-82-8 Benzene( 1-methylethyl) aromatic hydrocarbon 3/5 3/25 0.016 11
6 526-73-8 Benzene, 1,2,3 trimethyl aromatic hydrocarbon 4/5 7/25 0.03 10
7 95-63-6 Benzene, 1,2,4 trimethyl aromatic hydrocarbon 4/5 7/25 0.0086 10
8 611-15-4 Benzene, 1ethyl-2-methyl (ethyltoluene) aromatic hydrocarbon 4/5 5/25 0.049 16
9 620-14-4 Benzene, 1-ethyl-3methyl aromatic hydrocarbon 4/5 8/25 0.017 9
10 622-96-8 Benzene, 1-ethyl-4-methyl aromatic hydrocarbon 4/5 6/25 0.017 13
11 100-42-5 Styrene (benzene, ethenyl-) aromatic hydrocarbon 2/5 1/25 0.016 16
12 85-68-7 Benzyl butyl phthalate ester 2/5 1/25 0.016 16
13 123-72-8 Butanal aldehyde 2/5 1/25 0.016 16
14 67-71-0 Dimethyl sulfone sulfone 3/5 1/25 0.016 16
15 120-72-9 Indole nitrogen heterocycle 3/5 1/25 0.016 16
16 151-56-4 Aziridine,2-methyl (ethyleneimine) amine 3/5 3/25 0.01 11
17 112-53-8 1-Dodecanol alcohol 4/5 8/25 ,0.05 9
18 36653-82-4 1-Hexadecanol alcohol 4/5 8/25 ,0.05 9
19 629-76-5 1-Pentadecanol alcohol 3/5 3/25 0.016 11
20 112-70-9 1-Tridecanol alcohol 4/5 8/25 0.049 9
21 18172-67-3 B-Pinene cyclic monoterpene 3/5 3/25 0.016 11
doi:10.1371/journal.pone.0013813.t001
Figure 2. From melanoma and nevus to volatile signatures. Pictures from naevus (A) and melanoma skin lesion (D), H&E staining of biopsy
from naevus (B) and melanoma lesion (E), chromatograms from naevus (C) and melanoma (F). Some peaks are unique in melanoma (***), some are
increased (**) and some are decreased (*) in melanoma vs. naevi. (G, J and M) Chemical structure of pyridine, 3-hexanol and 2,5 dimethyl
benzenamine, and their retention time in the chromatograms (indicated by the arrow). (H, K and N) Mass spectra of the indicated peaks (extracted
spectrum, above) and mass spectra from the library (library hit and identification of the compound, bellow). (I, L and O) Frequency distribution of
these three compounds in blank (B), melanoma (M) and naevi (N) group, as well as their expression analysis (log of integrated signal) are presented (t-
test, mean6SEM). In (O) right panel n=16 for N and n=3 for M. Dimethyl benzenamine (2,5; 2,3; 2,4 or 2,6) is a volatile compound present in 19 out
of 25 naevi samples, in 4 out of 5 melanoma samples and detected in only one air sample. A peak of 2,5 dimethyl benzenamine is shown eluting at
17.8 min. This compound is common in both melanoma and naevi group.
doi:10.1371/journal.pone.0013813.g002
Melanoma Volatile Biomarkers
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13813abundant compound found on human skin (Table S4, p,0.0001,
see Discussion). Fuzzy logic analysis identified this volatile as one
of the 12 compounds that can be used to distinguish melanoma
from skin (Figure 4). Leave-one-out cross validation with variable
selection in each leave-one-out run was used to assess the
predictive performance of the fuzzy logic analysis. The area
under the Receiver-Operating characteristic Curve (ROC) is
determined as 0.936; indicating that these 12 compounds are able
to correctly classify melanoma with high sensitivity and specificity
(Figure 4B). A graphical representation of these data is presented
in the form of the heat map (Figure 4C).
Comparison of fresh and frozen volatile signatures in
melanoma biopsies
In Figure 5 the number of volatile compounds detected in each
group, as well as the number of compounds that overlap between
fresh naevi, fresh melanoma, frozen skin and frozen melanoma are
presented as a Venn diagram to illustrate the complex relationship
between the volatile fingerprints of the different sample sets. We
detected a total of 35 compounds unique to melanoma, and 3
compounds unique to and common to both fresh and frozen
melanoma samples. The availability of the fresh melanoma tissue
for research is limited and we sought to investigate whether the
frozen tissue will be suitable for this type of study. We documented
a differential expression of volatiles in frozen and fresh melanoma
samples as compared to the controls; however we did not observe
the complete overlap in these two sets of melanoma volatile
profiles. This was probably due to a difference in the type of
control tissue used and in the tissue preparation (fresh or frozen).
Although volatile expression profiling from frozen tissue has a
limited potential for clinical utility, here it served to demonstrate
the proof of principle.
In case of 3 volatile compounds tissue preparation methodology
(freezing/thawing) did not have an effect. Thus, despite the
differences in methodology, three compounds identified in fresh
tissue were still predictive of melanoma in frozen tissue. 4-methyl
decane, dodecane and undecane were detected from both fresh
and frozen melanoma at a significant level compared to the
Table 2. Six volatile compounds with significant increase in
frequency distribution from frozen melanoma (M-melanoma,
S-skin).
No CAS COMPOUND M S p-value
1 2847-72-5 Decane,4-methyl 18/21 4/20 ,0.0001
2 112-40-3 Dodecane 21/21 11/20 0.0006
3 17453-93-9 Dodecane, 5-methyl 19/21 11/20 0.0114
4 142-91-6 Isopropyl Palmitate 14/21 2/20 0.0083
5 629-62-9 Pentadecane 9/21 1/20 0.005
6 1120-21-4 Undecane 18/21 3/21 ,0.0001
doi:10.1371/journal.pone.0013813.t002
Figure 3. Differentially expressed volatile compounds in
melanoma vs naevi. The expression level of compounds as indicated
by log of integrated signal, in melanoma group (black bars, n=5) and
naevi group (grey bars, n=25) are shown in panels A, B and C. Data are
expressed as mean 6 STDEV, *p=0.05–0.09, **p=0.005–0.05,
***p=0.0001–0.005. In A: 2-propanamide* is 2-propanamide, 2-methyl;
benzene** is benzene, 1,3 dimethyl and phthalate*** is bis(2-ethylhexyl)
phthalate.
doi:10.1371/journal.pone.0013813.g003
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biomarkers. 4-methyl decane was present at significantly increased
frequency, while dodecane and undecane were present at
significantly increased both frequency and expression level.
Dodecane was also one of the 12 candidate volatiles identified
by fuzzy logic analysis. However, methylated benzenes, dimethyl
sulfone, ethyleneimine, nonane, indole and longer chain alcohols
initially detected in fresh melanoma samples, together with some
aldehydes (propanal, butanal) were not found in our frozen
samples, indicating that the volatile signature may have changed
due to the freezing process and prolonged storage. The results
from our frozen melanoma group have a different control,
skin instead of naevus (used as a control in our fresh group),
precluding a full comparison; however if a volatile is to be a true
melanoma biomarker, its presence should be detected neither in
skin, nor in nevus.
Discussion
In this paper we presented a novel approach for detecting
metabolites of melanoma and demonstrated a proof of principle
that a differential metabolic signature of melanoma does indeed
exist. Our results support the hypothesis that volatile metabolites
change as a result of cancerous process. This altered volatile
signature has the potential to develop into a new diagnostic tool. It
is particularly important for melanoma, since early detection of
melanoma is critical for a positive outcome for patients. Our
results indicate that combining HS-SPME with GC/MS to detect
volatile signatures from naevi and melanoma tissue is a valid
approach. A similar approach has been used to detect volatile
organic compounds (VOC) in breath of lung [9,10,11,12] and
breast cancer [13] and melanoma patients [14]. In this study, we
showed that after volatile collection tissue can be used for histology
analysis.
The current prevailing opinion is that many melanomas arise de
novo and only a subset of melanoma arises from the naevus [15,16].
In the current study, we used acquired melanocytic naevi (i.e.
moles) from volunteers as a control group to which our melanoma
samples were compared. Naevi are benign tumors of melanocytes
with an oncogene-induced senescent phenotype. Naevi exist in a
growth-arrested state predominantly induced by BRAF
V600E [17].
There is no literature record of volatiles released from naevi, and
this study is the first to address this question. Although most
volatiles present in naevi were also present in the melanoma
group, the level of these volatiles detected was significantly
different for 21 compounds (Figure 3). In addition, the volatile
signature from naevi revealed pyridine and 3-hexanol as specific
naevi compounds not found in melanoma (Figures 3 and 5).
The presence of pyridine implies a unique metabolism in naevi.
The number of naevi present during childhood is a predictor for
melanoma and it can also be an indicator of an early harmful UV
exposure, or both [18]. UV exposure, oxidative stress and reactive
oxygen species (ROS) induce breaks in DNA [19]. PARP-1
[Poly(ADP-ribose) polymerase-1] an enzyme involved in DNA
repair stimulates polymerization of ADP-ribose [20]. ADP-ribose
polymers are rapidly turned over and converted to free ADP-
ribose by the action of poly (ADP-ribose) glycohydrolase (PARG)
[21]. In this reaction NAD (nicotinamide adenine dinucleotide) is
used as a substrate and nicotinamide (a pyridine derivative) and
free ADP-ribose are produced. Thus, prolonged oxidative stress
depletes the NAD content of the cell [22]. Any metabolic event
which results in the breakdown of an NAD molecule requires re-
synthesis of NAD to maintain intracellular levels of this co-
enzyme. It is called Pyridine Nucleotide Cycle [23]. We postulate
that in the naevi, similar processes occur that may explain the
metabolic origin of pyridine as a nicotinamide derivative and a
unique volatile biomarker of naevi.
Analysis of volatiles from fresh melanoma tissue clearly indicates
a differential metabolic signature. The metabolic origin of most
volatiles detected in this study is complex and remains elusive.
Some of these compounds have also been reported as volatile
organic compounds (VOC) associated with cancer. Acetone
(Figure 3A) and styrene (Table 1) were significantly increased in
our fresh melanoma group and these two volatiles have also been
found in the blood of lung cancer patients [7]. Undecane was
detected in both fresh and frozen melanoma samples (Figure 3C
and Table 3), and has been reported as a potential marker for lung
cancer [24].
Our statistical analysis indicates that nonane (detected in all five
fresh melanoma samples) is 14 times more likely to be present in
melanoma, and this volatile was also identified as one of 8 breast
cancer biomarkers [13].
Increased levels of indole indicates increased melanin synthesis
[25]. Consistent with this, a recent study describing melanin
composition analysis (pyrolysis in combination with GC/MS)
reported styrene, benzene, pyrole, phenol, indole and their alkyl
derivatives as main compounds formed during this thermal
degradation [26].
Literature data on volatiles released from skin does exist [27,28].
A comprehensive study of human skin volatile compounds
identified mostly carboxylic acids. In addition C3-C9 aldehydes;
alkanes and alkenes; C4-C10 ketones and many heterocyclic
structures detected [27]. Skin, the largest body organ, is exposed to
many environmental toxins that are either oxidants themselves or
produce reactive oxygen species (ROS) [29]. Aldehydes in the skin
are generated by the oxidation of unsaturated fatty acids released
from membrane phospholipids by UV generated ROS. Consistent
with these previous studies, in the current study using frozen
tissue bank samples, we detected many aldehydes from frozen
skin and in particular nonanal (see Table S4). Nonanal is formed
by the oxidative degradation of sebaceous component, mainly
oleic acid [30].
Table 3. Volatile compounds with significantly increased
mean value (log integrated signal) in the frozen melanoma
group (t-test).
No CAS COMPOUND P-VALUE
1 104-76-7 1-Hexanol,2-ethyl 0.0125
2 107-18-6 2-Propen-1-ol 0.0002
3 5400-75-9 2H-Benzimidazol-2-one, 1,3-
dihydro-5-methyl-
,0.0001
4 20633-03-8 3,4-Hexanedione, 2,2,5-trimethyl- ,0.0001
5 117-81-7 Bis(2-ethylhexyl) phthalate 0.0087
6 138-86-3 D-Limonene 0.052
7 112-40-3 Dodecane 0.003
8 17453-93-9 Dodecane,5-methyl ,0.0001
9 222866 Oxime-,methoxy-phenyl 0.0006
10 2078-54-8 Propofol ,0.0001
11 4254-14-2 Propylene Glycol 0.0087
12 32487-71-1 Pyrrole-3-carbonitrile,
5-formyl-2,4-dimethyl-
0.0021
13 90-43-7 o-Hydroxybiphenyl 0.014
doi:10.1371/journal.pone.0013813.t003
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13813Figure 4. Fuzzy logic analysis of frozen skin and melanoma samples. A. list of the volatile compounds, their Goodman Kruskal Lambda
values, the number of selections in all (38) leave-one-out runs, and the percentage of how often they were selected. B. Receiver operating
characteristic curve (ROC). C. Heat map for the frozen data. Each column represents one sample. Each row represents one compound. Red colors
represent retention time (RT) values that are high above the average; blue colors represent RT-values that are low and much below average. The first
row represents the category; whether the sample belongs to the skin samples (left 20 columns with blue color in the first row) or to the melanoma
samples (rights 18 columns with red color in the first row). The light blue color represents a missing value. Misclassified in the leave one out method
are samples 4 and 12 from skin group, and samples 14 and 18 from the melanoma group.
doi:10.1371/journal.pone.0013813.g004
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[27]. It is part of the BTEX compounds, that are gaining more
attention as these compounds are found to be ubiquitous
pollutants both indoors and outdoors [31]. D-limonene is
significantly increased in both fresh and frozen melanoma,
however, it is likely that D-limonene is an air and/or cosmetic
contaminant because this compound was detected in blank air
samples (Table S5), and also in the frozen skin samples (Table S4).
Fuzzy logic analysis is a powerful methodology. Analysis of
frozen skin and melanoma revealed 12 potential biomarkers with
89% sensitivity and 90% specificity. A concern here is that the
biopsy collection procedure is unknown (samples were obtained
from CHTN, for details see Material and Methods section, Tissue
Collection) and may contribute to the unique volatile signature.
Any systematic difference in the collection of the two types of
samples could cause a different volatile profile. In addition,
prolonged storage of these frozen samples (up to one year) may
result in differential profile. However, one compound deserves
special attention, dodecane. This simple alkane was detected in
both fresh and frozen melanoma by all statistical tests used (Chi-
square test, t-test and fuzzy logic). This compound is a potential
candidate marker of melanoma in addition to 4-methyl decane,
and undecane. Further studies on large number of patients will be
necessary to confirm it. These alkanes may be products of
increased oxidative stress and lipid membrane peroxidation.
The methylated alkane, 4- methyl decane, was listed as one of
16 biomarkers of lung cancer [10]. The detection of methylated
volatiles from melanoma suggests increased methionine metabo-
lism [32]. Increased levels of dimethyl sulfone (Table 1) and formic
acid (methanoic acid, Figure 3B) were detected with HS-SPME
from fresh melanoma samples. Previous studies have demonstrated
a higher expression of methionine cycle genes in melanoma [33].
Methionine is the major source of the methyl groups necessary for
the methylation of DNA and other molecules [34] and
‘‘methionine dependence’’ (absolute requirement of methionine)
is a phenotype characteristic of tumor cells [35]. S-adenosyl
methionine (SAM) carries and donates methyl groups to facilitate
cellular replication and detoxification reactions. The human
metabolome database (HMDB) lists 118 methyltransferases,
enzymes that can use SAM as a methyl donor. Certain classes of
the large and diverse family of methyltransferases (I-III) have very
diverse substrates that include amines, alcohols, carboxylic acids,
thiols, sulfides, alkenes and alkanes [36,37]. Aberrant DNA
methylation represents a common mechanism of transcriptional
silencing seen in cancer and is also present in melanoma [38]. It
has been shown that cancer cells are subject to abnormal de novo
methylation [39]. Increased levels of DNA methyltransferases were
detected in some cancers [40,41]. By using a bioinformatics tool,
Oncomine Concept Map (OCM, http://www.oncomine.org)
Sreekumar et al. [42] predicted increased ‘‘methyltransferase
activity’’ among the metabolites up regulated in metastatic
prostate cancer. The highly methylated environment in human
melanoma cell lines (e.g., SkMel-28) has been reported, and both
COMT (Cathechol O-methyl transferase) and DNA methyltrans-
ferase-1 were found to be increased approximately five and eight
times, respectively [33]. Furthermore, it was published previously
that COMT activity is present in the skin [43], where it is involved
in the methylation of the o-dihydroxy phenolic and o-dihidrox-
yindolic melanogens, thus reducing their redox cycling and the
generation of free radicals [44]. A few methylated amino-acids
have been recently revealed in connection with cancer. Increased
levels of methyl glycine or sarcosine in plasma of prostate cancer
patients has been shown to be associated with its progression to
metastasis [42]. Also, methyl alanine has been identified as one of
the candidate biomarkers for pancreatic ductal adenocarcinoma
[45]. Our results show an increase in methylated aromatic
hydrocarbons (benzenes) and alkanes in melanoma. This is the
first evidence of methylation of small molecules or metabolites that
has been reported in connection with melanoma. With the advent
of metabolomics technologies and the increased interest in
metabolomics, we predict that more methylated metabolites will
be found, especially in the context of melanoma and cancer.
Comprehensive volatile metabolomic studies might also help in
improving melanoma classification. Finding a correlation between
volatile molecular signatures and clinical parameters of melanoma
will complement recent genotype-phenotype studies [46,47] and
ultimately lead to an improved targeted therapy.
Materials and Methods
Tissue collection
We obtained ethics approval from the Institutional Review
Board at the University of Miami and the Miami VA Healthcare
system. Biopsy samples were obtained from subjects recruited in
accordance with an approved University of Miami Institutional
Review Board (IRB) protocol (No. 2006117) and Veteran
Administration IRB protocol (No. 00762). A written consent form
was obtained from each subject. All naevi samples were collected
from the volunteers (asked not to wash 8 hours before the biopsy)
and were confirmed by histology analysis (by G. Elgart) using
hematoxylin & eosin staining. Each naevus was removed by using
a 3-mm punch device (AcuPunch, Acuderm, Inc). Fresh
melanoma samples were collected from patients scheduled for
the excisional biopsy irrespective of histotype or disease stage. No
exclusion criteria were used, except that all samples were from
patients over 21 years of age. The melanoma lesion was first
excised and then cut with a 3-mm punch device in order to obtain
the same sample size as for naevi. The reason why each melanoma
lesion was first excised and then cut using the punch biopsy
technique is because excisional biopsy of melanoma is a preferred
method to remove a malignant lesion [48]. We did not want to
Figure 5. A Venn diagram showing the number of volatile
compounds specific for each tested group as well as the
numbers of overlapping volatiles between the groups (e.g.,
naevi has 80 volatiles not expressed in any other group).
doi:10.1371/journal.pone.0013813.g005
Melanoma Volatile Biomarkers
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13813compromisethesafetyofpatientforresearchpurposes.Immediately
after the lesion was removed, a 3-mm punch biopsy on the excised
tissue was performed for our research purposes. We do not believe
that punch biopsy of melanoma tissue immediately after excision of
the tissue introduces anyartifact that could account for the sampling
difference. After biopsy and volatile collection, melanoma samples
were analyzed and confirmed by H&E staining. We also collected
and analyzed 17 control air samples to identify air contaminants.
The air was collected from the same room where biopsy of naevi
samplestookplaceandthewholeprocedure wasidentical totheone
with biopsy tissue. In addition, we obtained chromatograms from
the anesthetic used in the biopsies (1% Xylocaine/Epinephrine &
Na-bicarbonate). Eighteen frozenmelanomaand twenty frozen skin
samples were obtained from the CHTN tissue bank (Cooperative
Human Tissue Network). Prior to storage at the tissue bank these
samplesweresnap frozen(in liquid N2) within1 hour after biopsy to
quenchmetabolism,and kept at 270uC fornotmore than oneyear.
Frozen samples were also cut with the 3-mm punch device to obtain
a uniform size, placed in the 1.5 mL vial and thawed on ice for
1 hour [49] and later processed in the same way as fresh naevi and
melanoma samples.
Histology analysis
Hematoxylin/eosin staining was done at the Dermatopathology
Laboratory Services Department of Dermatology University of
Miami, Miller School of Medicine. All fresh and frozen samples
after volatile collection were put into formalin and confirmed by
histology analysis done at the Department of Pathology, Jackson
Memorial Hospital.
HS-SPME collection of volatiles
We used HS-SPME (head space-solid phase microextraction)
method to collect the volatiles [6,50,51]. This method uses a small,
portable device with a coated fiber to extract and collect volatile
compounds for analysis by gas chromatography. The biopsy
sample was placed in a vial (Agilent, No. 5182-0715, 1.5 mL, with
0.3 mL polyspring insert) and capped with a Teflon coated silicone
septum (Figure 1E). The sample was kept refrigerated for not more
than one hour. After that the sample was left at room temperature
for one hour to equilibrate. The headspace was sampled with a
polydimethysiloxane-divinylbenzene fiber for one hour at room
temperature (65-mm PDMS-DVB, Cat No. 57344-U, Supelco,
Bellefonte, PA, USA). Extraction selectivity depends on the type of
the fiber and the coating thickness. Since we are dealing with an
unknown complex matrix, we decided to use a fiber with broad
selectivity, non-polar PDMS/DVB. In order to achieve higher
sensitivity, the sample headspace should be as small as possible [6],
therefore we introduced the inner tube into the 1.5 mL vial. We
also decided to use a fiber of 65 mm, of medium thickness; a
general rule is that a thick fiber adsorbs more compounds;
however their diffusion from the fiber during thermal desorption is
slower. Analysis of air samples obtained in parallel with biopsy
collection (n=17) revealed 34 compounds that were present in at
least 40% of the samples (Table S5). Some components known to
elute from the fiber itself were excluded from this list (largely
siloxanes and their derivatives). Volatile analysis of the anesthetic
lidocaine used in the biopsy procedure of nevi samples revealed
the presence of additional volatiles: oxime-, metoxy-phenyl and
methylparaben. Lidocaine (5 mL) was placed in the vial, and the
volatiles were collected in the same fashion as described for tissue
samples in the Material and Methods section. In one biopsy of
melanoma, in addition to lidocaine, midazolam, propofol and
fentanyl were used as anesthetics. We analyzed volatiles from these
anesthetics and detected benzene, 2,4 diisocyanato-1-methyl and
diphenyl ether in addition to original anesthetics and the above
mentioned volatiles from lidocaine. No information was available
about anesthetics used to obtain frozen samples from CHTN.
Compounds like propofol and methoxy-phenyl oxime (Table 3), as
well as 2,4 diisocyanato-1-methyl benzene (Figure 4A) were most
likely released from anesthetics used in biopsy procedure.
Optimization of the HS-SPME conditions
The parameters such fiber coating (75 mm PDMS/Carboxen
Cat No. 57284-U and 65 mm PDMS/DVB), sample size (2- and
3-mm) as well as post biopsy time of volatile collection were
investigated (Figure S1). PDMS/Carboxen is predominantly used
for relatively small volatiles, compounds between 2–10 carbons
and low MW compounds (MW=30–225), while PDMS/DVB is
used for volatiles, amines, nitro-aromatic compounds, ranging
from 50–300 Daltons. We analyzed two 3 mm biopsy samples
from the same nevus with both fibers (TIC, total ion count, for
PDMS/DVB is about 91535, while for the PDMS/Carboxen is
70127) (Figure S1A). By comparing these two chromatograms we
observed that the difference is mainly quantitative and not
qualitative. The AMDIS postprocess comparison of these two
files is presented in the Figure S1B. From the 3-mm sample we
detected about 20 times more signal (Total Ion Count, TIC) than
from the 2-mm sample. Also, the number of identified compounds
was much larger (344 vs 260) (Figure S1C). Thus, in all subsequent
experiments, we performed a 3-mm punch biopsy. To examine
the effect of post biopsy collection time on volatile compounds, the
axilla sample from melanoma patient was collected and punched twice;
the first sample was analyzed within 3 hours of biopsy, while the
second sample was kept refrigerated overnight and analyzed the
next day. The integrated signal for each compound was divided by
the sum of signals from the whole sample (TIC) and the percent of
each volatile compound was calculated (Figure S1D). Comparison
of these two samples indicates loss of volatile compounds of about
30% in TIC. In the first sample, we identified 21 compounds,
while in the second we identified 25 compounds. Out of 17
compounds that were detected in both samples, eight showed
increase of $2 fold after 24 hours. These compounds were: 1-
Hexanol 2-ethyl-; 3-Methylbenzothiophene; Acetic acid butyl
ester; Diethyl Phthalate; Hexane 3,3-dimethyl-; Limonene;
Oxime- methoxy-phenyl-l and Phenol 2,4-bis(1-methylethyl)-
acetate. Volatile compounds that couldn’t be detected in the
24 hours/second sample, and thus were lost were: Benzene 1,4-
dichloro-, Dodecane, Ethanol and Methyl-hydrazine. The differ-
ence in volatile profile between these axilla samples indicate that
degradation process is indeed happening, even if the sample was
kept refrigerated overnight. In addition we analyzed the volatile
composition of two fresh skin melanoma samples within three
hours and after 6–8 hours post biopsy (data not shown). Approx-
imately 15% of compounds could not be detected after the
prolonged incubation at room temperature. Disappearance of
some volatiles after prolonged incubation indicates a need for a
stringent control of experimental conditions, in particular volatile
collection time post biopsy. Thus, in all fresh tissue samples
(melanoma and naevi) reported in this paper volatiles were
collected and analyzed within three hours post biopsy.
Gas Chromatography/Mass Spectrometry (GC/MS)
The PDMS/DVB fiber with collected volatiles was directly
injected onto a 0.75 mm i.d. injection port of Hewlett Packard
6890 gas chromatograph (Hewlett Packard, Avondale, PA) and
chromatographed on a non-polar DB-5MS column (model
No. J&W 128–5522, 25 m 60.2 mm i.d.x0.33 mm film) under
the following temperature program: 40uC for two minutes
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21 ramp to 270uC and hold for 5 minutes.
Helium carrier gas flow was run in constant flow at 0.7 mL min
21.
As volatile compounds elute from the column, they were
fragmented into ions (by electron ionization) and detected in the
quadrupole mass spectrometer. Each compound produced a
unique spectrum of molecular fragments (ions) with specific
masses and a fixed relative abundance. We used the Agilent
5973 mass spectrometer in the full scan mode (30–300 amu).
Preprocessing of the data
GC/MS metabolic profiling results in complex chromatograms
with huge differences in the relative abundance of different
compounds and with many co-eluting peaks that have to be
deconvoluted. We used the AMDIS deconvolution algorithm freely
available at www.amdis.net (Automated Mass Spectral Deconvolu-
tion and Identification software). Deconvolution finds ions whose
individual abundances rise and fall together over time, indicating
that they are from the same compound. AMDIS parameters were:
60% minimum matching factor, threshold-low, resolution-medium,
sensitivity-high, shape requirements-medium, adjacent peak sub-
traction-two,lowm/z 50,high m/z300. AMDIS generatesa report
file, where area under each peak represents the total absolute
amount of ions from each compound/metabolite present. Our
profiling quantifies metabolites based on their absolute mass ion
intensity. This eliminates the need for internal standards and makes
measurements of both known and novel metabolites possible
[52,53]. All components from AMDIS analysis were searched in
the NIST database (with one reported hit per compound and with a
minimummatchfactorsetto60%,meaningthatathresholdof60%
similarity was used for the spectral matching. After generating an
analysis report in the text file, we transferred the annotated
compound list to EXCEL for further processing. For each sample
identity of the compound; CAS or NIST number; retention time
and integrated signal were reported. Signal intensity represents the
log10 transformation of absolute ion counts in the area under the
deconvolutedpeak(Integratedsignal),thuswewereabletocompare
signals from multiple samples.
Data analysis
We used the Student t-test and Cochran-Mantel Haenszel Chi-
square test to detect statistical significance between our studied
groups. In addition, for analysis of frozen melanoma and skin
samples we used fuzzy logic methodology by Interrelation Miner
software from SystAim (http://www.interrelationminer.com). The
Interrelation Miner methodology analyses the relations between
the measured variables/volatiles statistically and constructs fuzzy
functions for every of these interrelations. With these fuzzy
functions, the software creates the membership matrix for each
group of samples such as the membership matrix for the group of
samples with Disease Present and membership matrix for the
group of samples with the Disease Not Present. Using the
membership matrix of each group of samples it can be calculated
how typical a sample is for each group. The prediction is simply
the group with the highest fuzzy membership.
Supporting Information
Figure S1 Optimization of the HS-SPME conditions. (A) Effect
of different fiber coatings (PDMS/Carboxen and PDMS/DVB)
on total ion count (TIC). (B) Comparative analysis of two different
chromatograms obtained with different fiber coatings from A. (C)
Effect of sample size on total ion count (S/N ratio $5) (D) Change
in % of TIC for volatile compounds analyzed from the same axilla
sample (two biopsies) within 3 hours (black) and after 24 hours of
biopsy (red) (sample was kept at +4uC).
Found at: doi:10.1371/journal.pone.0013813.s001 (2.26 MB TIF)
Table S1 Demographic data for volunteers and melanoma
patients used in this study (W-White, B-Black, IND-Indian).
Found at: doi:10.1371/journal.pone.0013813.s002 (0.01 MB
DOCX)
Table S2 Demographic data and histopathology reports for
melanoma patients used to obtain fresh biopsy samples.
Found at: doi:10.1371/journal.pone.0013813.s003 (0.01 MB
DOCX)
Table S3 Demographic data and histopathology reports for
frozen melanoma tissue samples.
Found at: doi:10.1371/journal.pone.0013813.s004 (0.01 MB
DOCX)
Table S4 Volatile compounds with significant increase in
frequency distribution from frozen skin (M) melanoma, S-skin.
(*-N/A).
Found at: doi:10.1371/journal.pone.0013813.s005 (0.01 MB
DOCX)
Table S5 Common compounds present at $40% of control air
blank samples.
Found at: doi:10.1371/journal.pone.0013813.s006 (0.01 MB
DOCX)
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